genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Apellis
Drug Discovery
StockWatch: M&A Talk Fuels Cytokinetics Stock Roller Coaster
Artificial Intelligence
StockWatch: French Raid Shows Little Effect on Nvidia Price
GEN Edge
StockWatch: Short Seller Briefly Dents Apellis Shares
Drug Discovery
Apellis Axing 25% of Staff, Shifting Resources to GA Drug
Drug Discovery
StockWatch: Apellis Shares Nosedive 73% on Safety Concerns
Cancer
StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy
Drug Discovery
Complementary Challenge: Apellis Throws Down the Gauntlet
News
Apellis Pharmaceuticals – APL-9
News
Apellis to Acquire Potentia, Four Years After Spinout
Scroll Up
Scroll Up
